Indinavir is an antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Indinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and mild elevations in indirect bilirubin concentration. Indinavir is a rare cause of clinically apparent, acute liver injury. In HBV or HCV coinfected patients, antiretroviral therapy with indinavir may result in an exacerbation of the underlying chronic hepatitis B or C. It is grouped under the following drug class(es): HIV-1 protease inhibitors. Its therapeutic use is listed as anti-infectives and antivirals. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Crixivan and indinavirum. Its PubChem CID is 5362440.
Indinavir
| CAS No | 150378-17-9 |
|---|---|
| Molecular Formula | C36H47N5O4 |
| Molecular Weight | 613.8 g/mol |
| Synonyms | (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N–tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Indinavir is an antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS).
The listed CAS number is 150378-17-9.
The listed molecular formula is C36H47N5O4.
The listed molecular weight is 613.8 g/mol.
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N–tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide.
The source lists Crixivan and indinavirum.